BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 8:39:00 PM | Browse: 422 | Download: 461
Publication Name World Journal of Gastroenterology
Manuscript ID 5424
Country/Territory China
2013-09-06 14:35
Peer-Review Started
2013-09-06 16:09
To Make the First Decision
2013-09-16 20:22
Return for Revision
2013-09-18 16:20
2013-09-27 23:07
Second Decision
2013-10-14 09:53
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-10-14 13:17
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-12-13 15:55
Publish the Manuscript Online
2014-01-20 16:41
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Meta-Analysis
Article Title Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: A systematic review
Manuscript Source Invited Manuscript
All Author List Qing Liu, Chen-Chen Feng, Er-Man Wang, Xiu-Juan Yan and Sheng-Liang Chen
Funding Agency and Grant Number
Funding Agency Grant Number
National Natural Science Foundation of China 31171106
National Natural Science Foundation of China 81070302
National Natural Science Foundation of China 81270463
Corresponding author Sheng-Liang Chen, MD, Professor, Department of Gastroenterology, Ren Ji Hospital, School of Medicine, Shanghai Institute of Digestive Disease, Shanghai Jiao Tong University, 145 Middle Shandong Road, Shanghai 200001, China. slchenmd@hotmail.com
Key Words Mosapride; Proton pump inhibitor; Gastroesophageal reflux disease; Systematic review; Combined therapy
Core Tip Prokinetic agents have been widely used to relieve the gastroesophageal reflux disease (GERD) symptoms, and mosapride is a selective 5-HT4 receptor agonist that can be safely used. We conducted a systematic review and meta-analysis to assess the potential benefits of the addition of mosapride to proton pump inhibitors (PPIs) in the treatment of GERD. Based on this research, mosapride combined therapy seems to be not more effective than PPI alone as first-line therapy. Whether it is effective in PPI-resistant patients needs to be determined.
Publish Date 2014-01-20 16:41
Citation Liu Q, Feng CC, Wang EM, Yan XJ, Chen SL. Efficacy of mosapride plus proton pump inhibitors for treatment of gastroesophageal reflux disease: A systematic review. World J Gastroenterol 2013; 19(47): 9111-9118
Url http://www.wjgnet.com/1007-9327/full/v19/i47/9111.htm
DOI http://dx.doi.org/10.3748/wjg.v19.i47.9111
Full Article (PDF) WJG-19-9111.pdf
Manuscript File 5424-Review.doc
Answering Reviewers 5424-Answering Reviewers.pdf
Copyright License Agreement 5424-Copyright Assignment.pdf
Non-Native Speakers of English Editing Certificate 5424-Language Certificate.pdf
Peer-review Report 5424-Peer Review(s).pdf
Scientific Editor Work List 5424-Scientific editor work list.doc